It has been asserted to support the hypothesis regarding tau aggregation inhibition as a potential strategy to treat AD.[88] MTC effectively inhibits the tau–tau binding interaction; however, the concentrations required for tau aggregation inhibition may prove toxic to humans when administered orally, as such high levels can result in accumulation within the intestine and liver. Here, MAPT is linked to Alzheimer disease.